Precision

Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency

Retrieved on: 
Mardi, mai 7, 2024
Research, Medical Devices, FDA, Genetics, Health Technology, Biotechnology, Health, Other Science, Science, CTA, Fast Track, Safety, Pharmacokinetics, Food, European Commission, OTC, Gene editing, Communication, Collection, IND, Therapy, Precision BioSciences, Patient, Civil service commission, Standard of care, Precision, Vaccine

ECUR-506 is iECURE’s in vivo gene insertion program designed to treat neonatal onset Ornithine Transcarbamylase (OTC) deficiency utilizing a PCSK9-specific ARCUS nuclease, licensed from Precision, that enables insertion of a functional copy of the OTC gene.

Key Points: 
  • ECUR-506 is iECURE’s in vivo gene insertion program designed to treat neonatal onset Ornithine Transcarbamylase (OTC) deficiency utilizing a PCSK9-specific ARCUS nuclease, licensed from Precision, that enables insertion of a functional copy of the OTC gene.
  • The Fast Track designation is designed to facilitate the development and expedite the review of therapeutics to treat serious conditions that fill an unmet medical need.
  • Provided relevant criteria are met, programs with Fast Track designation are eligible for accelerated approval and priority review as well.
  • “Congratulations to iECURE for this significant regulatory designation and for what it can potentially mean to patients with neonatal onset OTC deficiency.

Precision Aerospace Holdings, LLC Acquires Owens Machine and Tool Company

Retrieved on: 
Mardi, mai 7, 2024
Other Defense, Machinery, Contracts, Machine Tools, Metalworking & Metallurgy, Transportation, Defense, Travel, Other Manufacturing, Engineering, Air, Transport, Aerospace, Manufacturing, CNC, AS9100, Partnership, CIC, Titanium, Acquisition, ITAR, Precision, Growth

Dallas-based Precision Aerospace Holdings LLC (Precision), a leading manufacturer of precision machined aerospace and defense components, has acquired Owens Machine and Tool Company (Owens).

Key Points: 
  • Dallas-based Precision Aerospace Holdings LLC (Precision), a leading manufacturer of precision machined aerospace and defense components, has acquired Owens Machine and Tool Company (Owens).
  • Owens produces complex, multifaceted parts, tooling and prototypes utilizing multi-axis machine tools and best-in-class cutting tools.
  • It was established in 1986 to develop and sell complex machine components, primarily to the aerospace and defense industries.
  • “The Owens team has deep experience that expands our broad capabilities to provide world-class service to aerospace and defense industries.

Festool Releases Limited Editions That Take Portability and Precision to the Next Level

Retrieved on: 
Mardi, mai 7, 2024
KSC, TCL, Safety, CTC, Cordless, Yeti, Workflow, Portability, TSC, LED, Stiffness, Longevity, Precision

LEBANON, Ind., May 7, 2024 /PRNewswire/ -- Festool, a leading manufacturer of innovative, precision-engineered, and durable power tool solutions, today unveiled a range of limited-edition cordless combo kits and router solutions designed to meet the evolving needs of professionals while enhancing workshop and jobsite efficiency. Available beginning June 3, 2024, two limited-edition cordless combo kits, the limited-edition OF 1010 R REQ-F-Plus Router with Light Module, the Festool Level, and the limited-edition Summer Systainer are set to optimize performance for professionals no matter the specialty.

Key Points: 
  • Each kit is designed to kickstart or expand Festool cordless collections by providing convenience, performance, flexibility, and quality.
  • Precision Cutting: The TSC 55 K Cordless Track Saw offers unmatched power and accuracy that guarantees flawless cuts every time, plus a safety enhancing KickBackStop function.
  • Limited-Edition OF 1010 REQ-F-Plus + Light Module: Precision and Clarity For Every Job
    The OF 1010 REQ-F-Plus router, enhanced with an LED Light Module, offers unmatched precision and ease of use.
  • The Festool Level (577220) will be available at $65.00.

All Three Leading Independent Proxy Advisory Firms Recommend Norfolk Southern Shareholders Vote “FOR” Significant Boardroom Change on the BLUE Proxy Card

Retrieved on: 
Vendredi, mai 3, 2024
Professional Services, Finance, Trade, Egan-Jones Ratings Company, Norfolk Southern Railway, ISS, Safety, Annual general meeting, NSC, Blue, Thought, Precision, Glass, Management

Notably, all three proxy advisory firms also recommend voting AGAINST Norfolk Southern’s proposed executive compensation.

Key Points: 
  • Notably, all three proxy advisory firms also recommend voting AGAINST Norfolk Southern’s proposed executive compensation.
  • All three proxy advisory firms now support significant change at Norfolk Southern.
  • If shareholders support a majority change of the Board, they can ensure that operationally proficient management commences a network redesign and properly implements Precision Scheduled Railroading.
  • This three-year strategy, which differs greatly from Norfolk Southern’s resilience railroading model, has driven superior service, safety and long-term value at every other publicly-traded Class I rail.

Jim Barber, Former UPS COO and Member of Ancora’s Slate, Sends Letter to Norfolk Southern Shareholders Ahead of May 9th Annual Meeting

Retrieved on: 
Vendredi, mai 3, 2024
Professional Services, Finance, Slate, Trade, Teamster, PSR, Culture, Road, Precision, Private sector, Proxy, NS, Thought, Workforce, UPS, International, Transport, Safety, NSC, Accident, Policy, Burnout, Trust, Annual general meeting, International Brotherhood of Teamsters, Letter, Management

Vote on the BLUE Proxy Card to elect the entire Shareholder Slate at the Annual Meeting.

Key Points: 
  • Vote on the BLUE Proxy Card to elect the entire Shareholder Slate at the Annual Meeting.
  • I appreciate that many of you are evaluating what my colleagues and I have said in recent weeks about moving Norfolk Southern forward.
  • Both sides have obviously sent you a lot of information to consider and digest before votes are cast at the Annual Meeting.
  • My goal is to bring this same spirit of constructive thinking and teamwork to Norfolk Southern and its boardroom.

Integrated cancer biotech Infinitopes secures £12.8m seed financing to enhance its Precision Immunomics™ antigen discovery technologies to target five more cancers

Retrieved on: 
Jeudi, mai 2, 2024
Neoplasm, Medication, Cancer, Laboratory, Bias, Innovation, Big Pharma, University of Oxford, Octopus Group, Health care, Recurrence, Kindred, Vaccine, CRUK, Cancer Research Institute, Patient, LC-MS/MS, MHRA, Immune system, Associate, Precision, Growth

OXFORD, England, May 2, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announced the completion of a £12.8m seed funding round led by Octopus Ventures.  The round was heavily oversubscribed, also drawing in funds from Cancer Research Horizons, Cancer Research Institute, CRIS Cancer Foundation, Kindred Capital, Manta Ray, Martlet Capital, Meltwind Advisory, Saras Capital, Wilbe Capital, and expert angel investors. The total funds raised combine new equity investment and a prestigious non-dilutive award from Innovate UK's Future Economy Investor Partnership scheme.

Key Points: 
  • Since incorporation in 2021, Infinitopes has moved swiftly to cement its leadership position in cancer vaccines by overcoming three key challenges in the field.
  • Firstly, using its Precision ImmunomicsTM antigen discovery technologies, the Company can identify and rank tumour signatures, without prior bias, enabling the accurate selection of novel, synergistic tumour targets.
  • Secondly, Infinitopes continues to develop safe and effective, proprietary vector delivery systems, capable of stimulating durable T-cell responses necessary to prevent the recurrence of life-threatening cancer metastases.
  • Infinitopes' lead asset, a novel cancer vaccine called ITOP1, is scheduled to commence a phase I/IIa study in first line cancer patients in the third quarter of 2024.

Integrated cancer biotech Infinitopes secures £12.8m seed financing to enhance its Precision Immunomics™ antigen discovery technologies to target five more cancers

Retrieved on: 
Mardi, avril 30, 2024
Neoplasm, Medication, Cancer, Laboratory, Bias, Innovation, Big Pharma, University of Oxford, Octopus Group, Health care, Recurrence, Kindred, Vaccine, CRUK, Cancer Research Institute, Patient, LC-MS/MS, MHRA, Immune system, Associate, Precision, Growth

OXFORD, England, April 30, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announced the completion of a £12.8m seed funding round led by Octopus Ventures.  The round was heavily oversubscribed, also drawing in funds from Cancer Research Horizons, Cancer Research Institute, CRIS Cancer Foundation, Kindred Capital, Manta Ray, Martlet Capital, Meltwind Advisory, Saras Capital, Wilbe Capital, and expert angel investors. The total funds raised combine new equity investment and a prestigious non-dilutive award from Innovate UK's Future Economy Investor Partnership scheme.

Key Points: 
  • Since incorporation in 2021, Infinitopes has moved swiftly to cement its leadership position in cancer vaccines by overcoming three key challenges in the field.
  • Firstly, using its Precision ImmunomicsTM antigen discovery technologies, the Company can identify and rank tumour signatures, without prior bias, enabling the accurate selection of novel, synergistic tumour targets.
  • Secondly, Infinitopes continues to develop safe and effective, proprietary vector delivery systems, capable of stimulating durable T-cell responses necessary to prevent the recurrence of life-threatening cancer metastases.
  • Infinitopes' lead asset, a novel cancer vaccine called ITOP1, is scheduled to commence a phase I/IIa study in first line cancer patients in the third quarter of 2024.

Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024

Retrieved on: 
Mercredi, mai 1, 2024
Technology, Biotechnology, Nanotechnology, Health, Other Health, Pharmaceutical, Stem Cells, Oncology, Research, Infectious Diseases, Genetics, Fitness & Nutrition, Science, Clinical Trials, Congress, CTA, EASL, Gene editing, IND, Entrepreneurship, CccDNA, Precision BioSciences, Precision, HBV

Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that the company will present late-breaking preclinical data from its clinical candidate, PBGENE-HBV, for the treatment of chronic hepatitis B (HBV) during a poster presentation at the European Association for Study of the Liver (EASL) Congress 2024 being held June 5-8, 2024 in Milan, Italy.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced that the company will present late-breaking preclinical data from its clinical candidate, PBGENE-HBV, for the treatment of chronic hepatitis B (HBV) during a poster presentation at the European Association for Study of the Liver (EASL) Congress 2024 being held June 5-8, 2024 in Milan, Italy.
  • “We look forward to the opportunity to share the latest new preclinical safety data from our PBGENE-HBV clinical candidate at the EASL Congress,” said Jeff Smith, Co-Founder and Chief Research Officer at Precision BioSciences.
  • PBGENE-HBV is designed to safely eliminate cccDNA and inactivate integrated HBV DNA.
  • As we look ahead, we remain on track to file an investigational new drug (IND) and/or clinical trial application (CTA) in 2024.”
    Presenter: Emily Harrison, Senior Scientist - Hepatitis Research Leader, Precision Biosciences

ISS Recommends Shareholders Support Significant Change At Norfolk Southern by Voting the Blue Proxy Card “FOR” Five of Ancora’s Director Candidates

Retrieved on: 
Mardi, avril 30, 2024
Professional Services, Trucking, Other Professional Services, Logistics, Supply Chain Management, Transport, Banking, Other Transport, Slate, Trade, Norfolk Southern Railway, ISS, Safety, Annual general meeting, NSC, Canadian Pacific Railway, Shareholder, Proxy, Glass Lewis, TSR, Precision, Judgement, Rail transport by country, Disclosure, Management

ISS recommends that shareholders elect William Clyburn, Jr., Sameh Fahmy, John Kasich, Gilbert Lamphere and Allison Landry to the Company’s Board of Directors (the “Board”).

Key Points: 
  • ISS recommends that shareholders elect William Clyburn, Jr., Sameh Fahmy, John Kasich, Gilbert Lamphere and Allison Landry to the Company’s Board of Directors (the “Board”).
  • Previously, Glass Lewis recommended shareholders elect six of Ancora’s director candidates, including proposed CEO Jim Barber.
  • Notably, both ISS and Glass Lewis recommend AGAINST Norfolk Southern’s proposed executive compensation.
  • Miles are in key decision-making roles, we believe the institutional biases that have hindered Norfolk Southern will remain in place and stall value creation.

AGCO Showcases Precision Ag Innovation at AEM's Celebration of Modern Ag on the National Mall in Washington, DC

Retrieved on: 
Mardi, avril 30, 2024
Momentum, AGCO, AGCO Power, Mall, Washington Monument, Food, The Future of Food, Fendt, Farmer, AG, Soil, AEM, National Mall, Precision, Government, Agriculture

"Ag on the Mall is an ideal chance for policymakers and manufacturers to help farmers feed the world."

Key Points: 
  • "Ag on the Mall is an ideal chance for policymakers and manufacturers to help farmers feed the world."
  • The display includes the Fendt Momentum® planter, Massey Ferguson's new 500R sprayer, the fuel-flexible AGCO Power™ CORE75 engine, and Precision Planting's Radicle Agronomics™ soil testing lab.
  • Bill Hurley, AGCO Vice President of Government Affairs and AEM Ag Chair, sees the event as a crucial educational opportunity for all participants.
  • AGCO's booth will be located on the National Mall at Ninth Street NW, between the Washington Monument and the U.S. Capitol.